- Home
- DIBS vs ACTU Comparison
DIBS vs ACTU Comparison
Compare DIBS & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- ACTU
- Stock Information
- Founded
- DIBS 2000
- ACTU 2015
- Country
- DIBS United States
- ACTU United States
- Employees
- DIBS N/A
- ACTU N/A
- Industry
- DIBS Catalog/Specialty Distribution
- ACTU
- Sector
- DIBS Consumer Discretionary
- ACTU
- Exchange
- DIBS Nasdaq
- ACTU NYSE
- Market Cap
- DIBS 175.8M
- ACTU 153.1M
- IPO Year
- DIBS 2021
- ACTU 2024
- Fundamental
- Price
- DIBS $3.63
- ACTU $6.74
- Analyst Decision
- DIBS Buy
- ACTU
- Analyst Count
- DIBS 2
- ACTU 0
- Target Price
- DIBS $8.00
- ACTU N/A
- AVG Volume (30 Days)
- DIBS 207.6K
- ACTU 73.4K
- Earning Date
- DIBS 11-08-2024
- ACTU 11-13-2024
- Dividend Yield
- DIBS N/A
- ACTU N/A
- EPS Growth
- DIBS N/A
- ACTU N/A
- EPS
- DIBS N/A
- ACTU N/A
- Revenue
- DIBS $86,409,000.00
- ACTU N/A
- Revenue This Year
- DIBS $5.17
- ACTU N/A
- Revenue Next Year
- DIBS $7.90
- ACTU N/A
- P/E Ratio
- DIBS N/A
- ACTU N/A
- Revenue Growth
- DIBS N/A
- ACTU N/A
- 52 Week Low
- DIBS $3.37
- ACTU $5.51
- 52 Week High
- DIBS $6.30
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- DIBS 38.06
- ACTU N/A
- Support Level
- DIBS $3.42
- ACTU N/A
- Resistance Level
- DIBS $3.79
- ACTU N/A
- Average True Range (ATR)
- DIBS 0.16
- ACTU 0.00
- MACD
- DIBS -0.01
- ACTU 0.00
- Stochastic Oscillator
- DIBS 26.79
- ACTU 0.00
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.